Get the Stockscreener App
0.68
10.51%
-0.0799
After Hours:
.68
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Vaxart Inc stock is traded at $0.68, with a volume of 168.50K.
It is down -10.51% in the last 24 hours and down -2.72% over the past month.
VAXART INC
See More
Previous Close:
$0.7599
Open:
$0.6699
24h Volume:
168.50K
Relative Volume:
0.49
Market Cap:
$N/A
Revenue:
$237.26M
Net Income/Loss:
$16.33M
P/E Ratio:
11.47
EPS:
0.0593
Net Cash Flow:
$7.57M
1W Performance:
-10.51%
1M Performance:
-2.72%
6M Performance:
+70.77%
1Y Performance:
-35.85%
1-Day Range:
$0.6503
$0.69
1-Week Range:
$0.6503
$0.69
52-Week Range:
$0.33
$0.80
Vaxart Inc Stock (VXRT) Company Profile
Compare VXRT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VXRT
Vaxart Inc
|
0.68 | 0 | 237.26M | 16.33M | 7.57M | 0.0593 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-24 | Initiated | Oppenheimer | Outperform |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Nov-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-29-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jun-24-21 | Initiated | Jefferies | Buy |
| Jun-11-21 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
View All
Vaxart Inc Stock (VXRT) Latest News
Vaxart (VXRT) Institutional Ownership 2026 $VXRT - MarketBeat
MSN Money - MSN
Vaxart anticipates early 2027 primary efficacy readout while aiming for Q2 sentinel data release - MSN
Vaxart (VXRT) Reports Progress in Clinical Programs and Financia - GuruFocus
VXRT: Revenue surged and net income turned positive as clinical milestones and funding flexibility advanced - TradingView
Earnings call transcript: Vaxart’s mixed Q1 2026 results, EPS beats forecast By Investing.com - Investing.com South Africa
VXRT: Revenue doubled year-over-year, with clinical milestones and cash runway into Q2 2027 - TradingView
[S-1] Vaxart, Inc. Files IPO Registration Statement - Stock Titan
Earnings call transcript: Vaxart’s mixed Q1 2026 results, EPS beats forecast - Investing.com
Vaxart Q1 2026 Earnings Call Transcript - MarketBeat
Vaxart : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Vaxart targets Q2 data from 400-person oral COVID vaccine study - Stock Titan
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results - The Manila Times
Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vaxart (OTCQX: VXRT) swings to Q1 2026 profit on BARDA and collaboration revenue - Stock Titan
Vaxart (OTCQX: VXRT) swings to Q1 2026 profit as COVID trial advances - Stock Titan
Vaxart (VXRT) files ATM supplement to raise up to $49.8M via Sales Agents - Stock Titan
Vaxart extends cash runway into Q2 2027 with Dynavax partnership and targets 2026 data readouts - MSN
Vaxart (VXRT) director James B. Breitmeyer files initial Form 3 with no trades - Stock Titan
Vaxart (NASDAQ: VXRT) awards 78,800 RSUs and 157,400 options to director - Stock Titan
Earnings Preview: Vaxart to Report Financial Results Post-market on May 07 - Moomoo
Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET - The Manila Times
Vaxart to report Q1 2026 results May 7 and host stockholder chat May 8 - Pluang
[EFFECT] Vaxart, Inc. SEC Filing - Stock Titan
Q3 2025 Vaxart Inc Earnings Call Transcript - GuruFocus
VXRT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vaxart (OTCQX: VXRT) outlines 2025 governance, pay and ownership - Stock Titan
Akin, an Elite Global Law Firm - Akin
Vaxart Investors Come Up Empty in Trial Against Insider Fund (3) - Bloomberg Law News
BREAKING: Jury Clears Armistice Capital, Execs Of Securities Fraud - Law360
Book value per share of Vaxart, Inc. – MUN:NB11 - TradingView
Jury Clears Armistice Capital, Execs Of Securities Fraud - Law360
Did Hedge Fund 'Greed' Hurt Vaxart Investors? Jury To Decide - Law360
Vaxart announces $25M share purchase agreement - MSN
The 3 penny stocks you swore you'd never buy (but you'll check anyway) - MSN
Vaxart (OTCMKTS:VXRT) Stock Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
Vaxart, Inc. Files Form 8-K for Common Stock (VXRT) on April 23, 2026 – Company Details and SEC Compliance - Minichart
Vaxart adds James Breitmeyer to board of directors By Investing.com - Investing.com Australia
Vaxart Adds Veteran Biotech Leader to Board - TipRanks
Vaxart adds James Breitmeyer to board of directors - Investing.com
Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors to Enhance Clinical Development and Regulatory Expertise - Quiver Quantitative
Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors - The Manila Times
Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors - marketscreener.com
Press Release: Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors - Moomoo
Vaxart, Inc. Files Form 8-K with SEC – Company Information and Details for April 20, 2026 - Minichart
Armistice Capital Head Calls COVID Stock Rise 'Fun,' 'Lucky' - Law360
Vaxart amends lease to add Utah Avenue space, ends Harbor Way lease in May - Investing.com Canada
Vaxart amends lease to add Utah Avenue space, ends Harbor Way lease in May By Investing.com - Investing.com South Africa
Vaxart Inc Stock (VXRT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
Cap:
|
Volume (24h):